ArticleNature2019
FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.
Erratum issued Registry-linked trialAbstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02609269 (Prospective Expression Analysis Using The Decipher Genomics Resource for Intelligent Discovery), which is not on this map. Cited by 194 papers.
0numbers the graph read from it
0cells of the map it votes in
194citing papers in PubMed
10.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Expression Analysis Using The Decipher Genomics Resource for Intelligent Discovery (GRID)® and Data Sharing Program
Who cites it
194 citing papers in PubMed, 275 citations in OpenAlex.
- Epigenetic reprogramming of lineage switching in cancer.FEBS letters · 2026Review
- VNN1, upregulated by FOXA1, suppresses osteogenic differentiation and promotes inflammation in LPS-induced periodontal ligament stem cells.Odontology · 2026Article
- Article
- Pioneer transcription factors direct tissue-specific cohesin chromatin entry and three-dimensional genome organization.Nature genetics · 2026Article
- FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate.Histopathology · 2026Article
- Decoding 3D chromatin architecture reveals distinct enhancer classes underlying hierarchical gene regulation in prostate cancer.Genome biology · 2026Article
- Identification of targets of clinical FOXA1 mutants involved in EMT and immune suppression in prostate cancer.Communications biology · 2026Article
- Molecular determinants of AR-enhancer interaction and cistrome reprogramming in prostate cancer progression.Endocrine-related cancer · 2026Review
- 3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer.Endocrinology · 2026Review
- IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer.European urology · 2026Article
- FOXA1 loss drives basal/squamous de-differentiation of prostate cancer and induces an immunosuppressive tumor microenvironment.Nature communications · 2026Article
- Toward Personalized Treatment of Urogenital Cancers: The Role of Patient-Derived Organoids.Oncology and therapy · 2026Review
- FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity.Cell reports · 2026Article
- Single-nucleus multi-omics analysis of mouse small-intestinal Lgr5+ cell populations reveals Foxa3-induced Paneth cell-lineage differentiation.Communications biology · 2026Article
- Counteracting FOX proteins epigenetically control the herpesvirus lytic-latent balance.Nature communications · 2026Article
- Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance.Journal of the National Cancer Center · 2026Review
- Mechanisms and implications of epithelial cell plasticity in the bladder.Nature reviews. Urology · 2026Review
- Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer.Journal of the National Cancer Center · 2026Review
- Identify the PANoptosis signature and prognostic model via a multimachine-learning computational framework for bladder urothelial carcinoma.Cancer cell international · 2026Article
- Genetic and epigenetic mechanisms underlying treatment-induced neuroendocrine prostate cancer.Journal of the National Cancer Center · 2026Review
134 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
17 authors at 6 institutions in 2 countries.
Elizabeth J AdamsHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wouter R KarthausHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elizabeth HooverHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Deli LiuSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Antoine GruetCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zeda ZhangHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hyunwoo ChoComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rose DiLoretoPhysiology, Biophysics, and Systems Biology Program, Weill Cornell Graduate School, New York, NY, USA.
Sagar ChhangawalaComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yang LiuGenomeDx Bioscience, Vancouver, British Columbia, Canada.
Philip A WatsonHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elai DavicioniGenomeDx Bioscience, Vancouver, British Columbia, Canada.
Andrea SbonerSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Christopher E BarbieriSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Rohit BoseDepartments of Anatomy, Medicine and Urology, University of California, San Francisco, San Francisco, CA, USA.
Christina S LesliePhysiology, Biophysics, and Systems Biology Program, Weill Cornell Graduate School, New York, NY, USA.
Charles L SawyersHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. sawyersc@mskcc.org.
Memorial Sloan Kettering Cancer Center · USCornell University · USGenome British Columbia · CAHoward Hughes Medical Institute · USUniversity of California, San Francisco · USWeill Cornell Medicine · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0MWeill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LODA, MASSIMO · 2017 to 2021
$10.9MThe MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CARVER, BRETT STEWART · 2017 to 2021
$6.8MRole of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7MUnderstanding Resistance to Next Generation AntiandrogensR01CA155169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2012 to 2022
$3.8MTri-Institutional Training Program in Computational Biology & MedicineT32GM083937 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHRISTINI, DAVID J. · 2009 to 2018
$3.1MCollaborative genomic alterations and transcriptional control in prostate cancerR01CA233650 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BARBIERI, CHRISTOPHER E · 2019 to 2023
$2.8MCoordinate Regulation of Oncogenic Signaling Pathways in SPOP Mutant Prostate CancerR37CA215040 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BARBIERI, CHRISTOPHER E · 2018 to 2024
$2.6MTranslational Research in Oncology Training ProgramT32CA160001 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2011 to 2020
$2.0MInvestigating How a Balance of Negative and Positive ETS Factors Controls Prostate OncogenesisK08CA226348 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOSE, ROHIT · 2018 to 2022
$1.3MGenomic instability and DNA repair in a distinct molecular class of prostate cancK08CA187417 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BARBIERI, CHRISTOPHER E · 2014 to 2018
$865kHoward Hughes Medical InstituteNCI NIH HHS F99 CA223063NCI NIH HHS K08 CA187417NCI NIH HHS K08 CA226348NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS P50 CA211024NCI NIH HHS R01 CA155169NCI NIH HHS R01 CA193837NCI NIH HHS R01 CA233650NCI NIH HHS R37 CA215040NCI NIH HHS T32 CA160001NCI NIH HHS U54 CA224079NIGMS NIH HHS T32 GM083937
Abstract
Mutations in the transcription factor FOXA1 define a unique subset of prostate cancers but the functional consequences of these mutations and whether they confer gain or loss of function is unknown
Indexed as
MutationPhenotypeAmino Acid SequenceAnimalsBase SequenceBinding SitesCell DifferentiationCell LineageChromatinDisease ProgressionGene Expression Regulation, NeoplasticHepatocyte Nuclear Factor 3-alphaHumansMaleMiceMice, Inbred NODChromatinFOXA1 protein, humanHepatocyte Nuclear Factor 3-alpha
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02609269ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.